Assoc. Prof. Dr. Di Yang | Cardiovascular Pharmacology | Best Researcher Award
Fudan University | China
Assoc. Prof. Dr. Di Yang is a distinguished researcher in the field of cardiovascular pharmacology with an academic journey beginning at Harbin Medical University, where he completed both his B.S. and M.S. degrees in Pharmacy and Pharmacology, respectively, followed by a Ph.D. in Cardiovascular Pharmacology from the School of Pharmacy, Fudan University. Currently serving as an Associate Professor at the Human Phenome Institute, Fudan University, Dr. Yang has developed a remarkable research career with postdoctoral training at Fudan University’s Basic Medical Sciences and an extensive record of competitive research grants, including multiple projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Science and Technology Commission. His innovative work spans vascular biology, cardiovascular aging, epigenetics, and metabolic disorders, focusing on critical mechanisms involving pyruvate dehydrogenase kinase 4, histone methyltransferases SMYD2 and SMYD3, and m6A demethylase ALKBH5 in vascular remodeling, endothelial aging, and cardiac hypertrophy. As a prolific author, Dr. Yang has contributed significantly to high-impact journals with key publications such as The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy, Poly (ADP-ribose) polymerases 16 triggers pathological cardiac hypertrophy via activating IRE1α-sXBP1-GATA4 pathway, Histone methyltransferase Smyd2 drives vascular aging by its enhancer-dependent activity, Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation, H3K4 methyltransferase Smyd3 mediates vascular smooth muscle cell proliferation, migration and neointima formation, The histone methyltransferase DOT1L is a new epigenetic regulator of pulmonary fibrosis, Histone methyltransferase Smyd3 is a new regulator for vascular senescence.
Profile: Orcid
Featured Publications
Chen, M., & Yang, D. (2025). Current insights into obesity and m6A modification. Biomedicines, 13(9), 2164.
Chen, M., Su, H., Shu, M., Shen, F., Lu, Y., Wu, S., Su, Z., Yu, M., & Yang, D. (2024). The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy. Cell Death & Disease, 15, 285.
Su, H., Xu, J., Su, Z., Xiao, C., Wang, J., Zhong, W., Meng, C., Yang, D., & Zhu, Y. (2023). Poly (ADP-ribose) polymerases 16 triggers pathological cardiac hypertrophy via activating IRE1α–sXBP1–GATA4 pathway. Cellular and Molecular Life Sciences, 80, 159.
Su, H., Meng, C., Xu, J., Su, Z., Xiao, C., & Yang, D. (2022). Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation. Cell Death & Disease, 13, 899.